3-(4-氟苯基)-4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶 | 87642-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(4-氟苯基)-4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶
• 中文别名: 9-氟-11&amp#x3B2,17,21-三羟基-16&amp#x3B2-甲基孕-1,4-二烯-3,20-二酮21-异尼古丁酸酯
• 英文名称: 3-(4-fluorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo<4,3-c>pyridine
• 英文别名: 3-(4-Fluorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridine
• CAS: 87642-31-7
• 化学式: C₁₂H₁₂FN₃
• mdl: MFCD08460453
• 分子量: 217.246
• InChiKey: VCEDOGBTSALKRD-UHFFFAOYSA-N

物化性质

• 沸点：
  456.6±45.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲酸 、 3-(4-氟苯基)-4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶 在 聚合甲醛 作用下， 反应 3.0h， 以75%的产率得到3-(4-Fluorophenyl)-5-methyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine
  参考文献：
  名称：

  Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents

  摘要：

  A series of new 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines was synthesized and screened for in vitro [3H]prazosin displacement activity. The results correlated well with their antihypertensive activity in spontaneous hypertensive rats. 1-Benzyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyrid ine (50, L 16052) was selected for further pharmacological evaluations of its potency when administered orally to conscious renal hypertensive dogs.

  DOI：

  10.1021/jm00145a015
• 作为产物：
  描述：

  1-乙酰基-3-(4-氟苯甲酰基)哌啶-4-酮 在 盐酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 3-(4-氟苯基)-4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶
  参考文献：
  名称：

  Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents

  摘要：

  A series of new 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines was synthesized and screened for in vitro [3H]prazosin displacement activity. The results correlated well with their antihypertensive activity in spontaneous hypertensive rats. 1-Benzyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyrid ine (50, L 16052) was selected for further pharmacological evaluations of its potency when administered orally to conscious renal hypertensive dogs.

  DOI：

  10.1021/jm00145a015

文献信息

• [EN] SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM<br/>[FR] 4,5,6,7-TÉTRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES SUBSTITUÉES, LEUR UTILISATION EN TANT QUE MÉDICAMENT ET PRÉPARATIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：SANOFI SA

  公开号：WO2013037415A1

  公开（公告）日：2013-03-21

  The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

  该发明涉及式(I)的取代4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶，它们作为药物的用途，以及包括它们的药物制剂。式(I)的化合物对TASK-1钾通道起作用。这些化合物特别适用于治疗或预防心房心律失常，例如心房颤动（AF）或心房扑动。
• Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase
  作者：Jeffrey T. Bagdanoff、Rama Jain、Wooseok Han、Daniel Poon、Patrick S. Lee、Cornelia Bellamacina、Mika Lindvall

  DOI：10.1016/j.bmcl.2015.06.063

  日期：2015.9

  A series of structure based drug design hypotheses and focused screening efforts drove improvements in the potency and lipophilic efficiency of tetrahydro-pyrazolopyridine based ERK2 inhibitors. Elaboration of a fragment chemical lead established a new lipophilic aryl-Tyr interaction resulting in a substantial potency improvement. Subsequent cleavage of the lipophilic moiety led to reconfiguration of the ligand bound binding cleft. The reconfiguration established a polar contact between a newly liberated N-H and a vicinal Asp, resulting in further improvements in lipophilic efficiency and in vitro clearance. (C) 2015 Elsevier Ltd. All rights reserved.
• Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B Virus
  作者：Buyu Kou、Zhisen Zhang、Xingchun Han、Zheng Zhou、Zhiheng Xu、Xue Zhou、Fang Shen、Yuan Zhou、Xiaojun Tian、Guang Yang、John A. T. Young、Hongxia Qiu、Giorgio Ottaviani、Alexander Mayweg、Wei Zhu、Hong C. Shen、Haixia Liu、Taishan Hu

  DOI：10.1021/acs.jmedchem.3c01145

  日期：2023.10.26
• Pharmacologically active pyrazolo(4,3-c)pyridines
  申请人：GRUPPO LEPETIT S.p.A.

  公开号：EP0086422B1

  公开（公告）日：1987-09-30
• 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：Ashton T Wallace

  公开号：US20060069116A1

  公开（公告）日：2006-03-30

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.